When they raise the Cash, then the drug development segment comes into play. The consumer product segment is such a great business that CVSI needs to handle the biopharma side very carefully. Don't get me wrong the biopharma segment adds some value and it's promising but I'll say 10 to 20% at the most right now. When they get the cash and the ball starts rolling with the IND and Phase I, then we can expect some value added. I'm being very conservative anyways and it still looks great.
This is all just my honest opinion. The market can get crazy like today and have an euphoric run any day because the trends of the company and the CBD market are so strong. We will find out in the next couple of weeks to a month.
Market Data 
Markets 
AI
